SCM
ZNTL icon

Squadron Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Squadron Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07M Buy
426,000
+26,000
+7% +$104K 0.64% 33
2026
Q1 		$936K Buy
+400,000
New +$1.03M 0.34% 33

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM

Squadron Capital Management's ZNTL Position: Q2 2026 in Review

Squadron Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 1.9% in Q2 2026, buying an estimated $275K and bringing the position to 3,700,000 shares worth $17.9M. The position accounts for 5.57% of the portfolio, ranked #6.

Squadron Capital Management first reported a position in ZNTL in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Squadron Capital Management held 3,700,000 shares of Zentalis Pharmaceuticals worth $17.9M as of Q2 2026.
  • Squadron Capital Management bought 69,000 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $275K.
  • Zentalis Pharmaceuticals made up 5.57% of Squadron Capital Management's portfolio in Q2 2026, its #6 holding.
  • Squadron Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.